New drug may help delay ageing in humans

Image
Press Trust of India Houston
Last Updated : Feb 18 2019 | 2:55 PM IST

Researchers, including one of Indian origin, have developed a promising drug that significantly increases muscle size, strength and metabolic state in aged mice, and may help delay ageing process in humans.

As we age, our bodies increasingly lose the ability to repair and rebuild degenerating skeletal muscles, said researchers from the University of Texas Medical Branch (UTMB) in the US.

Beginning around age 35, muscle mass, strength and function continually decline as we get older, according to the study published in Biochemical Pharmacology.

This can dramatically limit the ability of older adults to live fully active and independent lives.

"There are no treatments currently available to delay, arrest or reverse age-related muscle degeneration," said Harshini Neelakantan, a research scientist at UTMB.

"These initial results support the development of an innovative drug treatment that has the potential to help the elderly to become fitter, faster and stronger, thus enabling them to live more active and independent lives as they age," Neelakantan said.

"We identified a protein in muscle stem cells that appears to be responsible for their age-related dysfunction, and then developed a small molecule drug that limits the effects of this protein," said Stanley Watowich, an associate professor at UTMB.

"By resetting muscle stem cells to a more youthful state, we were able to rejuvenate them so that they could more effectively repair muscle tissues," Watowich said.

In the study, aged mice with a muscle injury were treated with either the drug or a placebo.

Following seven days of drug treatment, researchers found that the aged mice that received the drug had more functional muscle stem cells that were actively repairing the injured muscle.

In the treated group, muscle fibre size doubled, and muscle strength increased by 70 per cent, compared with the placebo group.

In addition, the blood chemistry of the drug-treated and untreated mice was similar, suggesting no adverse drug effects were occurring.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 18 2019 | 2:55 PM IST

Next Story